Biovica has secured SEK 122 million through a capital raise to scale up sales. The core of the initiative is DiviTum TKa, a blood-based test that measures cell division and provides healthcare providers treatment-effect insights in days instead of months. The capital will primarily be used to accelerate sales in the US and build capacity for larger volumes. We reached out to CEO Anders Rylander for a comment.
Read the full interview at biostock.se:
SEK 122 million gives Biovica the power to scale up globally
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/